A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

Summary

The purpose of the study is to assess the success of a single administration of Staccato alprazolam compared with placebo both in rapidly terminating a seizure episode within 90 seconds and with no recurrence of seizure(s) up to 2 hours after investigational medicinal product (IMP) administration.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Stereotypical Prolonged Seizures

Eligibility basics and study details

Study type

Interventional

Phase

Phase 3

Ages

12 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

UCB Biopharma SRL

Last updated on ClinicalTrials.gov

September 29, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites